PepGen Inc./$PEPG
PepGen shares are trading lower after the company announced it will discontinue its experimental Duchenne muscular dystrophy therapy following disappointing mid-stage study results.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Ticker
$PEPG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
79
ISIN
US7133171055
Website
PepGen Inc. Metrics
BasicAdvanced
$55M
-
-$3.14
1.39
-
Price and volume
Market cap
$55M
Beta
1.39
52-week high
$3.17
52-week low
$0.88
Average daily volume
218K
Financial strength
Current ratio
4.946
Quick ratio
4.786
Long term debt to equity
16.51
Total debt to equity
19.905
Management effectiveness
Return on assets (TTM)
-40.84%
Return on equity (TTM)
-75.45%
Valuation
Price to book
0.6
Price to tangible book (TTM)
0.6
Price to free cash flow (TTM)
-0.653
Growth
Earnings per share change (TTM)
-2.35%
3-year earnings per share growth (CAGR)
-58.01%
PepGen Inc. News
AllArticlesVideos
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
Benzinga·1 day ago
PepGen to discontinue development of experimental Duchenne therapy; shares drop
Reuters·2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PepGen Inc. stock?
PepGen Inc. (PEPG) has a market cap of $55M as of May 30, 2025.
What is the P/E ratio for PepGen Inc. stock?
The price to earnings (P/E) ratio for PepGen Inc. (PEPG) stock is 0 as of May 30, 2025.
Does PepGen Inc. stock pay dividends?
No, PepGen Inc. (PEPG) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next PepGen Inc. dividend payment date?
PepGen Inc. (PEPG) stock does not pay dividends to its shareholders.
What is the beta indicator for PepGen Inc.?
PepGen Inc. (PEPG) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.